Locametz® 25 µg

Locametz 25 µg

Locametz®▼ (gozetotide) is a diagnostic kit for radiopharmaceutical preparation.

Indication

Locametz®▼, after radiolabelling with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

  • Primary staging of patients with high-risk PCa before primary curative therapy,
     
  • Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy,
     
  • Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.

Summary of Product Characteristics (SmPC)

Sweden Denmark Norway Finland Iceland

Practical information about Locametz®▼ 

The marketing authorisation holder for Locametz®▼ is Novartis Europharm Limited, distributed in the Nordic and Baltic regions by SAM Nordic.

Further information about this medicinal product can be obtained from the representative of the marketing authorisation holder: SAM Nordic, Tel: +46 8 720 58 22, info@samnordic.se

 

▼This medicinal product is subject to additional monitoring.